Showing results (11-20 of 95) with videos related to
Sort By:
Pageof 10
Endocrine, Metabolic & Immune Disorders Drug Targets|March 17, 2015
Metformin and Inflammation: Its Potential Beyond Glucose-lowering EffectYoshifumi SaishoDiseases (Basel, Switzerland)|May 26, 2018
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin TreatmentKazutoshi Sugiyama, Yoshifumi SaishoNutrients|December 19, 2020
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-ReviewJun Inaishi, Yoshifumi SaishoDiabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 24, 2019
Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 DiabetesTaichi Nagahisa, Yoshifumi SaishoClinical Pharmacology : Advances and Applications|April 15, 2022
Exenatide Once Weekly for Management of Type 2 Diabetes: A ReviewJun Inaishi, Yoshifumi SaishoJournal of Clinical Medicine|February 28, 2018
Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and DiabetesJun Inaishi, Yoshifumi SaishoDiabetes Research and Clinical Practice|June 2, 2006
Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartanYoshifumi Saisho, Naoko Komiya, Hiroshi HiroseJOP : Journal of the Pancreas|December 2, 2014
Relationship between body mass index and pancreas volume in Japanese peopleKinsei Kou, Yoshifumi Saisho, Masahiro Jinzaki, et al.Journal of the Endocrine Society|August 18, 2021
Revisiting Regulators of Human β-cell Mass to Achieve β-cell-centric Approach Toward Type 2 DiabetesHironobu Sasaki, Yoshifumi Saisho, Jun Inaishi, et al.Diabetes Research and Clinical Practice|May 1, 2007
Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese type 2 diabetic subjectsYoshifumi Saisho, Taro Maruyama, Hiroshi Hirose, et al.Pageof 10